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A Ab bs st tr ra ac ct t
Translation of research findings into clinical practice is an important aspect of medical progress.
Even for the early stages of genomics, research aiming to deepen understandings of underlying
mechanisms of disease, questions about the ways in which such research ultimately can be useful
in medical treatment and public health are of key importance. Whilst some research data may not
apparently lend themselves to immediate clinical benefit, being aware of the issues surrounding
translation at an early stage can enhance the delivery of the research to the clinic if a medical
application is later found. When simple steps are taken during initial project planning, the
pathways towards the translation of genomic research findings can be managed to optimize long-
term benefits to health. This piece discusses the key areas of collaboration agreements,
distribution of revenues and recruitment and sample collection that are increasingly important to
successful translational research in genomics.
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C Co or rr re es sp po on nd de en nc ce e
The translation of research findings into clinical practice is an
important aspect of medical progress. Even for the early
stages of genomics research, which aims to deepen our
understanding of underlying mechanisms of disease,
questions about the ways in which such research ultimately
can be useful in medical treatment and public health are of
key importance. The aim of this paper is to put forward
concrete ways to enhance the process of translation by
focusing on the key considerations that need to be taken into
account in the early planning stages of a research project
when the translation of research findings into clinical use
may seem quite remote. Whilst some research data may not
apparently lend themselves to an immediate clinical benefit,
being aware of the issues surrounding translation at an early
stage can enhance the delivery of the research to the clinic if a
medical application is later found. When simple steps are
taken during initial project planning, the pathways towards
the translation of genomic research findings can be managed
to optimize long-term benefits to health. This paper discusses
the key areas of collaboration agreements, distribution of
revenues, and recruitment and sample collection that are
increasingly important to successful translational research in
genomics. Such consideration is timely in light of the recent
report on Genomic Medicine by the House of Lords in the
UK, which recognized translation as vital to realizing the
potential of genomic medicine, and the need to address
various obstacles to successful translation [1].
W Wh ha at t   d do oe es s   t tr ra an ns sl la at ti io on n   m me ea an n   i in n   t te er rm ms s   o of f   g ge en no om mi ic cs s? ?
A significant proportion of genomics research is still at a
very early stage in terms of clinical outcomes. Despite early
excitement about the results of genome-wide associationstudies, recent debates in the scientific literature highlight
that most of the variants found through this methodology
account for only a small degree of the relative risk of
developing a disease or a trait, and the findings collectively
explain only a very small proportion of the underlying
genetic component of most diseases [2,3]. Critics of current
methodologies advocate increased focus on the study of rare
variants and gene-gene and gene-environment interactions
[4,5]. Whilst there may be debates about the appropriate
allocation of funding to different research methodologies
within genomics research, it is clear that genomics research
will continue to advance rapidly.
Although there is uncertainty as to the actual concrete
benefits that are likely to accrue from genomics research
[6-9], there seem to be three major areas into which clinical
outcomes of genomics research could be grouped. Firstly,
the research may lead to better understanding of physiology
and disease states [10]. It is hoped that these advances will
influence and improve current treatment practices. For
example, a recent paper outlines the developments in the
understanding of the genetic architectures of plasma lipids
and lipoproteins, anticipating that these advances may
improve classification, diagnosis and treatment of dyslipid-
emias [11]. Secondly, the research may lead to the develop-
ment of new or better diagnostic tools - for example, for
disease stratification or predictive tests for common complex
diseases [3]. It is hoped that the development of such tests
may contribute to early diagnosis, screening programs or
strategies that delay or prevent the onset of disease. Genetic
tests exist for many rare genetic disorders, including cystic
fibrosis and hypertrophic cardiomyopathy. Early predictive
tests or useful diagnostic tests may also be developed for
common complex disorders in the future. Moreover,
pharmacogenetic tests are also in development (for example,
recent research has identified genetic variants linked to
susceptibility to developing statin-induced myopathy [12])
and some are already in clinical use [13] (for example, in the
prescribing of abacavir for the treatment of HIV [14]).
Commentary on recent efforts to translate the results of
genome-wide association studies into direct-to-consumer
tests has indicated the difficulties in developing tests proven
to have clinical validity and utility, and regulating their sale
[15-17]. Third, genomics research may lead to the develop-
ment of new therapeutics, although there has not been the
rapid discovery of novel and perfect drug targets that was
anticipated by some when the human genome was first
sequenced [18].
Much recent commentary has focused on the achievements
and limitations of genomics research to date [19-21], and on
further directions to advance science and maximize clinical
utility [22,23]. This paper aims to contribute to this
endeavor by examining how initial steps can maximize the
utility of this immense research effort.
T Tr ra an ns sl la at ti io on n   v vi ia a   c co om mm me er rc ci ia al li iz za at ti io on n
Commercialization is an important means by which inno-
vations in biomedicine are translated into clinical practice,
and whilst the positive and negative aspects of industry
involvement in biomedicine are still hotly debated, commer-
cialization is a reality in translational research [24]. The
development of clinical products for patients usually occurs
with the involvement of industry, for the oft-cited reason
that the regulatory approval processes to which biomedical
products are subjected require significant time and money
[25,26]. In genomics, the importance of industry in
translation is likely to vary with the difficulty and length of
development of a product following a basic science
discovery, as well as the degree of regulatory oversight and
approval of the product in question.
There are increasingly permeable boundaries between basic
and applied, academic and industrial science. Many genomics
research projects are now set up with a commercial partner
(for example, Procardis [27]); some European Union
projects call for the involvement of small and medium
enterprises [28], or a commercial partner may become
involved later in the life of a project [29]. The necessity of
effective collaboration between industry, academia, the
charitable sector and the UK National Health Service for
translational research was highlighted in the recent UK
House of Lords Genomic Medicine Report [1]. Factors such
as the reputedly high revenues gained by public research
institutions following the patenting of new inventions, and
institutional policies and pressures have meant that many
public science researchers are encouraged to patent and
develop their research findings [30-32]. However, it remains
the case that later stage development of innovations is
conducted primarily by or in partnership with companies.
Given these realities of commercialization, there are a number
of issues that should be considered early in a genomics
research program. In this paper we discuss the types of
agreements that must be put in place, the factors that
funders and research institutions need to consider and the
importance of informing participants to ensure public trust
in research. This process does not need to be costly or time
consuming. Moreover, consideration and appropriate atten-
tion at an early stage may save time and money later on.
S Se et tt ti in ng g   t th he e   g gr ro ou un nd d   r ru ul le es s: :   c co ol ll la ab bo or ra at ti io on n   a ag gr re ee em me en nt ts s
Genomics research frequently involves collaborations
between many researchers from different institutions in
multiple countries. Research collaborations are forged
between researchers who have different but complementary
expertise, skills and resources. These collaborations are often
based on informal relationships; previous experience of
working on research projects together or on the reputation
that an individual or group may have gained in the field.
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agreements will be put in place between the researchers,
funders and institutions involved in the research. The
primary aim of such contracts is to articulate the nature and
aims of the project and the roles and responsibilities of each
party, but they do not necessarily articulate the fine detail of
all aspects of the project. They also will need to cover,
amongst other things, issues such as ownership of intellec-
tual property (IP) - including defining the ownership of prior
held IP and that developed during the project - confiden-
tiality and material transfer.
Other aspects that might benefit from early consideration
and articulation include rights of research and experimental
use, and publication and dissemination rights. Overly
restrictive agreements that constrain future research direc-
tion and prevent researchers developing and pursuing
autonomous research are rarely appropriate or warranted
for academic research. Some delay in publication for the
purposes of obtaining IP protection may be necessary, but
the delay should not be protracted. Policies and best
practices for university licensing have been developed that
emphasize reservation of research rights and licensing in a
way to maximize use and development of inventions, and
may provide useful guidance [33-35].
Putting these agreements in place is not straightforward.
Each of these contracts raises different issues for the parties
involved and can be time-consuming to negotiate and
develop. Moreover, where projects receive funding from
multiple sources and involve multiple parties, sometimes in
many different countries, each with different legal regimes,
the challenges are magnified. Additionally, it can be
exceptionally difficult to draft agreements that both accom-
modate the current organization of the research and are also
flexible and provide appropriate solutions for future
possibilities. Model agreements have been developed to
assist parties and these could be a useful starting point
[36,37]. Efforts in some jurisdictions to standardize agree-
ments have made the process of developing these agreements
easier, but this has not happened in all jurisdictions.
Especially in complex projects spanning multiple institu-
tions and jurisdictions, agreements need to be tailored to the
specific situation [38]. Moreover, agreements need to be
drafted in a manner sensible and sensitive to downstream
development. An overly restrictive agreement put in place at
an early stage, although conceived with the best of
intentions, may in effect rule out any development if it
includes conditions that are extremely difficult or impossible
to fulfill for potential commercial partners.
Whilst there may be increased transaction costs associated
with consideration of these issues at an early stage, these are
outweighed by two advantages of having clear agreements in
place before the commencement of research. Firstly, the
process of drafting these agreements means that full
consideration is given to the issues, which can mean that
potential pitfalls are recognized and avoided. Secondly, if
disputes do later arise, the agreements will hopefully provide
a basis and mechanism for their resolution.
These agreements are essential. Although precise details of
problems are often kept confidential due to their commercial
sensitivity, insufficient attention to detail in this area has led
to significant stumbling blocks for potentially valuable
projects, sometimes in the initial stages of getting a project
off the ground, whereas for others problems with agreements
have not become apparent until later in the research project.
D Di is st tr ri ib bu ut ti io on n   o of f   r re ev ve en nu ue es s
Research institutions, funding bodies and individual
researchers may all have an interest in protecting possibly
profitable outcomes from the work that they fund, host, or
execute. Increasingly in recent years, universities have seen
the commercialization of research as a potential source of
income and as a means to fund further research. Similarly,
funding bodies may have a direct interest in promoting the
commercialization of the research that they fund, as this may
generate revenue for the future [39].
Whilst there is the potential for ‘blockbuster’ revenues from
patents in genomics, such as the benefit Stanford University
and the University of California gained in terms of additional
research funding from the licensing revenues of the Cohen-
Boyer patent [40], this is exceptional. Patents are expensive
to acquire and maintain, and costs may not match up to the
benefits. In addition, the patenting landscape in genomics is
complex, with the potential for multiple patents covering
genetic sequences or variants, methods and techniques. The
development of a genetic diagnostic test for a common
complex disorder may therefore require the careful negotia-
tion of licensing agreements with multiple stakeholders,
each of whom will seek a percentage of revenue as a royalty.
Huge license fees are not likely to be workable in relation to
patents that make a small contribution to a larger product. It
is unrealistic in such a circumstance to expect and bargain
on the basis of wanting a huge percentage of profit; to do so
may ultimately block translation [41].
Participants are an essential partner in genomics research
projects; research cannot proceed without access to samples.
This fact necessarily raises the question of whether the
donors of the genetic material have a right to compensation
or reward; so-called ‘benefit sharing’ [42]. This compensa-
tion, whether financial or non-financial, might be at the time
of donation of the sample, or at some future point in time, if
there are ultimately profits generated from the research
project [43,44]. Some projects might provide for individual
benefits, such as the feedback of clinically relevant results
such as blood pressure from initial assessments or medical
treatment [45,46]. Others might aim to provide community
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question of sharing of benefits is complex, and a full
consideration is beyond the scope of this paper. We agree with
Forsberg et al. [48] that research is necessary and desirable
for future development of healthcare, and excessive focus on
individual benefits at the expense of solidarity and altruism
may provide a barrier to research. One way to consider benefit
sharing in genomic research is to focus less on individual
benefits, and more on benefits for public health [48].
One aspect of benefit sharing in the literature is the question
of ensuring fair and reasonable access to the innovation for
those who participated in research to develop it. Access is
important not only for those who directly participated in the
research in question through donation of samples, but also
for the population as a whole; innovations of genomics
research should be available to those who need them, not
only the privileged few. Questions of access to healthcare are
not specific to genomics; they take place within a much
broader context of healthcare and social justice and equality.
The general assumption is that in a system of social health-
care, there is automatic access to the medical innovations
through regular healthcare provision. However, with
increasing financial pressures on health services, it may not
in fact be reasonable to assume that genomic innovations
will be standard of care, especially where such innovations
are very expensive, such as in the case of Herceptin in the
UK. If a social healthcare system does not pay for the
innovation in question for those whose genetic information
helped to develop the innovation, does the commercial
developer have a duty to do so? In some cases, this may be
reasonable. But where an innovation was developed for a very
small population, where a large proportion of them were
involved in the genomic research, then a requirement that the
innovation be provided free of charge may mean that there is
effectively no market for a product. In such circumstances
charitable and government funding, as well as tax
concessions, may be helpful to make development possible.
Both universities and funding bodies may be in a better
position than individual researchers to use their consider-
able negotiating power and access to legal advice to develop
frameworks for translation of their funded research that will
maximize patient access. Funding bodies such as the Gates
Foundation, whose prime concern is ensuring the equitable
distribution to vulnerable populations of innovations
developed through funded research, use IP rights and
contractual means to ensure this. For example, researchers
seeking access to data generated by the MalariaGEN project
are required to sign up to an agreement that includes the
following: ‘if the use of the data gives rise to IP that could
support health benefits in the developing world, the owner
of the IP agrees to license it on a reasonable basis for use in
the developing world and on a preferential basis to the
countries whose citizens are the subject of the database’
[49]. What remains undefined, however, is what ‘licensing
on a reasonable basis’ means. Others who promote ‘global
social responsibility’ propose concrete licensing models for
university inventions that aim to improve access for the
developing world [50]. Vigilant attention to the actual
impact of these license agreements is necessary to ensure
they are reasonable, flexible and assist in providing effective
sustainable translation of genomic research.
R Re ec cr ru ui it tm me en nt t   a an nd d   s sa am mp pl le e   c co ol ll le ec ct ti io on n: :   c co on ns se en nt t   a an nd d
c co om mm me er rc ce e   
The expected benefit to patients from genomics research is a
major motivating factor for participants in genomics research;
even if participants have no expectation of personal benefit,
they are generally motivated by potential improvements in the
health of the population [51]. At the same time, participants
often have reservations about commercial involvement in, and
profit from, research on their samples and information, as well
as concerns about who will benefit. Beliefs about the potential
for research to give rise to improvements in healthcare may
result in tension if coupled with misconceptions about what
this would involve. If these tensions are not appropriately
managed, this could be problematic for the sustainable
translation of research results in genomic research that relies
on the continuous recruitment of patients and controls.
However, simple steps could help to sustain recruitment and
enhance public trust in the research and translation process.
Amongst potential research participants, there is a wide
range of opinion opposing or supporting commercial
involvement in genomic research. Those who question the
extent of commercial involvement in research may express
concerns about industry profiting from what they see as
‘their’ biological material [52]. Groups such as Genewatch
UK express concerns about the costs of products, or that
commercial involvement may skew research agendas
towards commercially viable products at the expense of
other outcomes that may be of importance [53]. Meanwhile,
the involvement of commercial partners in research may be
explicitly promoted by some patient groups, such as PXE
International, that actively seek out and encourage industry
to investigate and develop therapies for their diseases [54].
The Genetic Interest Group, an umbrella organization
representing the interests of those affected by various
genetic diseases, both receives funding from industry and
actively participates in research, often with commercial
partners and with the explicit aim of producing outputs such
as pharmacological treatments [55]. Others may even be
prepared to pay to be involved in commercial genomics
research projects [56].
I In nf fo or rm mi in ng g   p pa ar rt ti ic ci ip pa an nt ts s
Consent forms may vary in the information they provide.
Where research explicitly involves a commercial partner, it
is likely that the consent process will have taken the possibility
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then have been informed of commercial involvement before
consenting. Difficulties may arise where archived data are
used or where data are shared from studies taking place within
a purely academic context. Consent information from such
studies may refer to possible sharing of data or their use in
other ‘research’ or ‘scientific research’ or ‘medical research’,
but rarely mentions industry. Hence, participants may not be
aware of the possibility of downstream involvement of
industry, private profit and patenting.
The context of consent is well known to be of crucial
importance to shaping participants’ expectations and under-
standings of what research will involve. Many taking part in
clinical research still partake of the ‘therapeutic misconcep-
tion’ that they may benefit from research, even if it has been
explained to them that benefit is unlikely [57]. Likewise,
research taking place within a purely academic context, such
as a research institute or hospital, especially where publicly
funded, is likely to lead at least some participants to think of
the research as basic research rather than research leading
to possible commercial activity [58]. Researchers cannot
assume that participants will realize that the translation of
research into concrete medical outcomes generally involves
commercial partners with possible profits for some.
Moreover, research indicates that commercial involvement
is something recruits wish to know about, even if it will not
change their decision to participate [59-61]. Research also
tells us that fostering trust between potential participants
and researchers holds the key to sustainable recruitment
practices [51,60,62]. Being explicit about downstream
commercial involvement may assist in fostering such a
climate of openness and trust. It also means that consent is
obtained for future commercial collaboration without the
need for re-consent on this issue.
C Co on ns se en nt t   a an nd d   c co om mm me er rc ce e: :   w wh ha at t   a ar re e   r re ec cr ru ui it ts s   t to ol ld d? ?
Many studies taking place within an academic context under-
standably make no reference to the issue of the translation of
research findings. For example, the highly respected
Whitehall studies, run from University College, London, and
currently funded by the Medical Research Council, British
Heart Foundation, the National Heart Lung and Blood
Institute and the National Institute of Ageing, have been
taking place over several decades within different levels of
the UK civil service. These studies have produced voluminous
and much utilized research findings, including data that
have been used in genomic research. The consent form for
the latest phase of the project (the Whitehall Phase 9
Consent Form [63]) does not make explicit mention of
whether or not there is any commercial involvement, as the
following extract indicates:
‘I consent to participate in the genetic component of the
Stress and Health Study. DNA will be prepared from my
blood cells for the study of genetic influences which may be
relevant to diabetes, heart disease, stroke and cognitive
function, and their risk factors. DNA will be stored for use
in projects undertaken by the Stress and Health Study and
its collaborators. I understand that no information found
from the DNA will be given to me and that the information
will be treated in the strictest confidence. I understand that
the samples and information will be coded and used
anonymously for research purposes only.
17. I agree that the blood samples that I have given and the
information gathered about me will be stored by the Stress
and Health Study for possible use in future research
projects. Samples and information will be anonymised, so
that I will not be identified, before being used in future
research projects. All my personal information will be
treated in the strictest confidence in accordance with the
Data Protection Act (1998) and samples in accordance with
the Human Tissue Act (2004).’
This consent form makes it clear that samples and data may
be used in future research projects, and as such leaves open
the possibility that such future research projects may lead to
translational outputs with commercial components.
However, where a research project may share data in future
research projects with research groups involving commercial
partners, it may be advisable specifically to mention the
possibility of this and of outputs with financial rewards for
some parties.
The Procardis Programme aims to discover novel suscepti-
bility genes for coronary artery disease and involves colla-
boration between various European universities as well as
commercial partners [27]. Therefore, the consent form
explicitly mentions the element of commercial partners and
future translation of research:
‘I understand that the University of Oxford, and its
academic and commercial partners in the study, will use
the results to try to improve the diagnosis and treatment of
patients (including, for example, patenting and developing
new drugs), and that I shall not benefit financially from my
participation.’
Other projects that contemplate data sharing may
specifically address the question of commercial outcomes in
their consent forms. For example, the model consent form
developed for the National Human Genome Research
Institute Medical Sequencing Project [64] specifically
addresses this question:
‘3. Financial Compensation/Costs
You will not be paid to participate in this project. Your
blood (or other tissue) samples and your medical
information will be used only for research purposes and
http://genomemedicine.com/content/1/9/87 Genome Medicine 2009, Volume 1, Issue 9, Article 87 Hawkins et al. 87.5
Genome Medicine 2009, 1 1: :87will not be sold. It is possible that some of the research
conducted using your samples or information eventually
will lead to the development of new diagnostic tests, new
drugs or other commercial products. Should this occur,
there is no plan to provide you with any part of the profits
generated from such products.’
The Kadoorie Study of Chronic Disease in China is a
collaborative, longitudinal study between the Clinical Trials
Service Unit at the University of Oxford and the Chinese
National Centre for Disease Control involving 500,000
recruits. Data recorded include lifestyle data, such as
smoking, and several clinical measures, such as blood
pressure and lung function, and a blood sample is taken.
Recruits are to be monitored for 10 to 20 years. This project
has explicitly ruled out commercial involvement. The consent
form for this project (available on application [65]) specifies:
‘I understand that all information provided by me will be
treated confidentially, and that the Chinese National Centre
for Disease Control and the University of Oxford that are
responsible for the whole project will use the results to try
to improve the prevention and treatment of common
disease, and that I shall not benefit financially from my
participation. The information and blood samples collected
will not be used for any commercial purposes.’
Such a statement is open to interpretation in different ways.
Especially given that the results of such a study can be
expected to have widespread significance for populations
worldwide [66], it seems highly likely that the results will
then feed into understandings of disease that help ground
the development of commercial products. Close attention to
what is being specified in consent forms about commercial
use of participants’ data and samples, and end results, is
advisable. Whilst researchers collecting samples and
performing initial analysis of data may have no intention of
commercial activity, data sharing practices complicate
promises that there will be no commercial involvement.
P3G (the Public Population Project in Genomics) is an
international consortium to promote collaboration between
researchers in the field of population genomics that develops
tools to facilitate data sharing in genomics. It has developed
a generic consent form [67] for adaptation for research
projects that includes a disclaimer about commercial
involvement in research:
‘COMMERCIALIZATION
I understand that with proper oversight, results and
samples may be exchanged with researchers in other
countries, including those from commercial companies, for
use in specific biomedical projects. I will not receive any
personal financial benefit from the commercialization of
any test or product that may result.’
A clear recommendation is that the simplest, most direct and
most honest approach is to indicate explicitly the possibility of
commercial involvement in any consent forms and back-
ground study information, where there is any chance that
research data might be used later on for such purposes. The
use of archived data for translational research is likely to be
consistent with original consent so long as commercial
involvement was not explicitly ruled out. However, for current
research, best practice is to be explicit about the possibility of
commercial outputs. This would help in countering the
possible misconception whereby some recruits may distin-
guish between ‘pure’ research taking place in a university or
other academic context, and research with links to commercial
outcomes [68]. It is also in line with findings about
information that recruits would wish to be given [51,59,61].
R Re ep pr re es se en nt ta at ti iv ve e   r re ec cr ru ui it tm me en nt t   a an nd d   e eq qu ui it ta ab bl le e   t ta ar rg ge et ti in ng g   o of f
t tr ra an ns sl la at ti io on n
The availability of healthcare, including access to the fruits
of translation, is influential in attitudes to research
participation, and these links need to be thought about
carefully. Those who participate in research knowing that
their healthcare is well provided for may well have different
concerns to those individuals or groups whose healthcare
needs are poorly served. Attitudes are markedly different in
different countries and between different groups and it is
vital for recruitment processes to understand this [69].
Groups with unmet health needs may feel reluctance to
participate in research and this is especially the case where
resource allocation is seen as unfair, as research amongst
African Americans suggests [70]. It seems unlikely to be a
coincidence that Swedes, who have generally good access to
medical resources, often profess indifference to the sources
of funding for research [51,71], whereas African Americans,
many of whom lack health insurance and thus assured
healthcare provision, have shown suspicion towards the
motivations of researchers and their potential financial and
personal rewards [70]. It is vital that robust levels of
recruitment take place amongst certain underrepresented
groups [72], especially as these are groups most likely to
experience large burdens of ill health [69]; indeed, represen-
tative recruitment is now mandated in the US for reasons of
equity as well as scientific integrity [73]. Researchers have
limited control over large social issues, which require much
broader efforts to improve equality and justice. However,
forward planning about how the benefits of research
translation may be fed back to participating groups and due
care and attention to the recruitment process may assist in
boosting participation rates as well as being a real
contribution to health care justice. Ensuring that research
directions and research agendas include attention to a full
range of causal pathways, such as gene-environment inter-
actions [22], may also in the long term help more effectively
to address some of the reasons behind health disparities
between different groups.
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i in n   g ge en no om mi ic cs s
• Make sure appropriate and effective agreements are in
place before commencement of research.
• Keep expectations of profits to reasonable levels, and do
not let a desire for profit block translation of research
into clinically useful innovations.
• Recognize and utilize the power of institutions and
funding bodies to help ensure that innovations can be
utilized for the maximum benefit to patients around the
world.
• Address research participant concerns about commer-
cialization, and ensure that research participants are
fully informed through informed consent procedures
about the potential commercial outcomes of research.
C Co on nc cl lu us si io on ns s
Different clinical outcomes of genomics research will be
best suited to different pathways of translation and
development. There will be much greater investment in the
development of a therapeutic, with its associated
regulatory approval, than in recommendations of changes
to lifestyle or medical treatment practices; private invest-
ment may be more appropriate and necessary in some
areas than others. IP protection is likely to be important in
the development of new innovations from genomics
research. It should, however, be used sparingly and
sensitively, in accordance with the best practices developed
by organizations such as the OECD and the National
Institutes of Health [34,35,41].
Translation need not only be about the generation of
monopoly profits for the pharmaceutical industry. Ultimately,
translation should be about ensuring that the benefits of
genomics research reach those in the community who have
the need and will benefit from them. When research
institutions are planning genomics research, this goal should
be kept in mind, and arrangements should be put in place to
facilitate translation right from the beginning.
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